Enliven Therapeutics (NASDAQ:ELVN) Sets New 1-Year Low After Insider Selling

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report)'s stock price reached a new 52-week low during trading on Wednesday following insider selling activity. The company traded as low as $15.14 and last traded at $15.82, with a volume of 365172 shares changing hands. The stock had previously closed at $17.87.

Specifically, COO Anish Patel sold 6,667 shares of Enliven Therapeutics stock in a transaction dated Monday, April 7th. The stock was sold at an average price of $18.04, for a total value of $120,272.68. Following the transaction, the chief operating officer now directly owns 316,643 shares of the company's stock, valued at $5,712,239.72. The trade was a 2.06 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Wall Street Analyst Weigh In

Separately, HC Wainwright upped their price target on shares of Enliven Therapeutics from $37.00 to $39.00 and gave the stock a "buy" rating in a research report on Friday, March 21st.

Enliven Therapeutics Trading Up 1.8 %

The business has a 50 day simple moving average of $20.31 and a two-hundred day simple moving average of $23.29. The stock has a market cap of $823.41 million, a price-to-earnings ratio of -8.84 and a beta of 1.03.

Remove Ads

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last posted its quarterly earnings results on Thursday, March 13th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.53) by $0.07. The company had revenue of $0.03 million during the quarter. Research analysts anticipate that Enliven Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

Hedge Funds Weigh In On Enliven Therapeutics

Several large investors have recently added to or reduced their stakes in ELVN. FMR LLC grew its stake in Enliven Therapeutics by 3.2% during the 4th quarter. FMR LLC now owns 6,495,871 shares of the company's stock worth $146,157,000 after buying an additional 199,692 shares during the last quarter. Polar Capital Holdings Plc grew its position in shares of Enliven Therapeutics by 267.6% during the fourth quarter. Polar Capital Holdings Plc now owns 2,389,668 shares of the company's stock worth $53,768,000 after acquiring an additional 1,739,668 shares during the last quarter. Vanguard Group Inc. boosted its stake in Enliven Therapeutics by 2.9% during the 4th quarter. Vanguard Group Inc. now owns 1,975,655 shares of the company's stock valued at $44,452,000 after purchasing an additional 55,283 shares during the period. Janus Henderson Group PLC grew its position in Enliven Therapeutics by 27.9% in the 4th quarter. Janus Henderson Group PLC now owns 1,331,877 shares of the company's stock worth $30,001,000 after purchasing an additional 290,153 shares during the last quarter. Finally, Pictet Asset Management Holding SA raised its holdings in shares of Enliven Therapeutics by 16.3% during the fourth quarter. Pictet Asset Management Holding SA now owns 972,293 shares of the company's stock valued at $21,877,000 after buying an additional 135,969 shares during the last quarter. 95.08% of the stock is currently owned by institutional investors.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.